G
Gabriella Pichert
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 55
Citations - 4410
Gabriella Pichert is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 28, co-authored 54 publications receiving 4169 citations. Previous affiliations of Gabriella Pichert include London Bridge Hospital & Guy's Hospital.
Papers
More filters
Journal ArticleDOI
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek,Tara M. Friebel,Christian F. Singer,D. Gareth Evans,Henry T. Lynch,Claudine Isaacs,Judy Garber,Susan L. Neuhausen,Ellen T. Matloff,Rosalind A. Eeles,Gabriella Pichert,Laura Van T'veer,Nadine Tung,Jeffrey N. Weitzel,Fergus J. Couch,Wendy S. Rubinstein,Wendy S. Rubinstein,Patricia A. Ganz,Mary B. Daly,Olufunmilayo I. Olopade,Gail E. Tomlinson,Joellen M. Schildkraut,Joanne L. Blum,Timothy R. Rebbeck +23 more
TL;DR: Among a cohort of women with BRCa1 and BRCA2 mutations, the use of risk-reducing mastectomy was associated with a lower risk of breast cancer, first diagnosis of breastcancer, all-cause mortality, breast cancer-specific mortality, and ovarian cancer- specific mortality.
Journal ArticleDOI
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule
Michele Ghielmini,Shu Fang Hsu Schmitz,Sergio Cogliatti,Gabriella Pichert,Jörg Hummerjohann,Ursula Waltzer,Martin F. Fey,Daniel Betticher,Giovanni Martinelli,Fedro A. Peccatori,Urs Hess,Emanuele Zucca,Roger Stupp,Tibor Kovacsovics,Claudine Helg,Andreas Lohri,Mario Bargetzi,Daniel Vorobiof,Thomas Cerny +18 more
TL;DR: In patients with FL, the administration of 4 additional doses of rituximab at 8-week intervals significantly improves the EFS andCirculating normal B lymphocytes and immunoglobulin M plasma levels decreased for a significantly longer time after prolonged treatment, but the incidence of adverse events was not increased.
Journal ArticleDOI
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Antonis Antoniou,Antonis Antoniou,Amanda B. Spurdle,Amanda B. Spurdle,Olga M. Sinilnikova,Olga M. Sinilnikova,Sue Healey,Sue Healey,Karen A. Pooley,Karen A. Pooley,Rita K. Schmutzler,Rita K. Schmutzler,Beatrix Versmold,Beatrix Versmold,Christoph Engel,Christoph Engel,Alfons Meindl,Alfons Meindl,Norbert Arnold,Norbert Arnold,W. Hofmann,W. Hofmann,Christian Sutter,Christian Sutter,Dieter Niederacher,Dieter Niederacher,Helmut Deissler,Helmut Deissler,Trinidad Caldés,Trinidad Caldés,Kati Kämpjärvi,Kati Kämpjärvi,Heli Nevanlinna,Heli Nevanlinna,Jacques Simard,Jacques Simard,Jonathan Beesley,Jonathan Beesley,Xiaoqing Chen,Xiaoqing Chen,Susan L. Neuhausen,Susan L. Neuhausen,Timothy R. Rebbeck,Timothy R. Rebbeck,Theresa Wagner,Theresa Wagner,Henry T. Lynch,Claudine Isaacs,Claudine Isaacs,Jeffrey N. Weitzel,Jeffrey N. Weitzel,Patricia A. Ganz,Patricia A. Ganz,Mary B. Daly,Mary B. Daly,Gail E. Tomlinson,Gail E. Tomlinson,Olufunmilayo I. Olopade,Joanne L. Blum,Joanne L. Blum,Fergus J. Couch,Paolo Peterlongo,Siranoush Manoukian,M. Barile,Paolo Radice,Csilla Szabo,Lutecia Pereira,Lutecia Pereira,Mark H. Greene,Mark H. Greene,Gad Rennert,Gad Rennert,Flavio Lejbkowicz,Flavio Lejbkowicz,Ofra Barnett-Griness,Ofra Barnett-Griness,Irene L. Andrulis,Irene L. Andrulis,Irene L. Andrulis,Hilmi Ozcelik,Hilmi Ozcelik,Anne-Marie Gerdes,Anne-Marie Gerdes,Maria A. Caligo,Maria A. Caligo,Yael Laitman,Bella Kaufman,Bella Kaufman,Roni Milgrom,Eitan Friedman,Eitan Friedman,Susan M. Domchek,Katherine L. Nathanson,Ana Osorio,Gemma Llort,Roger L. Milne,Javier Benítez,Javier Benítez,Ute Hamann,Frans B L Hogervorst,Frans B L Hogervorst,Peggy Manders,Marjolijn J L Ligtenberg,Ans M.W. van den Ouweland,Susan Peock,Susan Peock,M. Cook,M. Cook,Radka Platte,Radka Platte,D. Gareth Evans,Rosalind A. Eeles,Gabriella Pichert,Carol Chu,Diana Eccles,Rosemarie Davidson,Fiona Douglas,Andrew K. Godwin,Andrew K. Godwin,Laure Barjhoux,Laure Barjhoux,Sylvie Mazoyer,Sylvie Mazoyer,Hagay Sobol,Violaine Bourdon,François Eisinger,Agnès Chompret,Agnès Chompret,Corinne Capoulade,Brigitte Bressac-de Paillerets,Gilbert M. Lenoir,Marion Gauthier-Villars,Claude Houdayer,Dominique Stoppa-Lyonnet,Georgia Chenevix-Trench,Georgia Chenevix-Trench,Douglas F. Easton,Douglas F. Easton +137 more
TL;DR: Differences in the effects of the FGFR2 and MAP3K1 SNPs between BRCA1 and BRCa2 carriers point to differences in the biology of BRC a1 and bRCA2 breast cancer tumors and confirm the distinct nature of breast cancer in BRC A1 mutation carriers.
Journal ArticleDOI
Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)
Michele Ghielmini,Shu-Fang Hsu Schmitz,Sergio Cogliatti,Francesco Bertoni,Ursula Waltzer,Martin F. Fey,Daniel Betticher,Hubert Schefer,Gabriella Pichert,Rolf A. Stahel,Nicolas Ketterer,Mario Bargetzi,Thomas Cerny +12 more
TL;DR: Single-agent rituximab is active in MCL, but the addition of four single doses at 8-week intervals does not seem to significantly improve response rate, duration of response, or EFS after treatment with the standard schedule.
Journal ArticleDOI
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antonis C. Antoniou,Rachel Hardy,Leslie G. Walker,D G R Evans,A Shenton,Rosalind A. Eeles,Susan Shanley,Gabriella Pichert,Louise Izatt,S. Rose,Fiona Douglas,Diana Eccles,Patrick J. Morrison,J. Scott,R.L. Zimmern,Douglas F. Easton,Pharoah Pd +16 more
TL;DR: Carrier prediction algorithms provide a rational basis for counselling individuals likely to carry BRCA1 or BRCa2 mutations and their widespread use would improve equity of access and the cost-effectiveness of genetic testing.